← Leaderboards
Jonathan P Schneck
Johns Hopkins University
$20,504,328
Attributed
$21,602,555
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$41,044,381 · 20
By mechanism
P41$13,152,947 · 5
P01$12,612,520 · 3
R01$10,279,672 · 4
R21$2,494,440 · 5
R33$2,216,534 · 2
R43$288,268 · 1
Top collaborators
- Hai-Quan Mao4 shared
- Jordan Green2 shared
- Bruce J Mccreedy1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Martin G Pomper$38,517,075
- William George Nelson$34,555,726
- Elizabeth Marion Jaffee$29,780,612
- William B Isaacs$27,729,214
- Alan W Partin$6,119,110
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteCellsAntigensIn VivoResearch PersonnelBaseImmunotherapyTechnologyDesignEngineeringResponseIn VitroAntigen-Presenting CellsTumorInnovationSignal TransductionMalignant NeoplasmsImmune ResponseMemoryCd4 Positive T LymphocytesComplexParticleImmuneFunding
Grant awards (87)
The Johns Hopkins Translational ImmunoEngineering (JH-TIE)$1,149,953
P41 · FY2025 · EB · contact PI
Identification of cancer neoepitope-specific T cells using novel high-throughput hydrogel based platforms$406,871
R33 · FY2025 · CA · contact PI
TR&D Project 1$326,246
P41 · FY2025 · EB · contact PI
Administrative Core$135,251
P41 · FY2025 · EB · contact PI
The Johns Hopkins Translational ImmunoEngineering (JH-TIE)$1,605,313
P41 · FY2024 · EB · contact PI
Administrative Core$644,149
P41 · FY2024 · EB · contact PI
Identification of cancer neoepitope-specific T cells using novel high-throughput hydrogel based platforms$428,438
R33 · FY2024 · CA · contact PI
TR&D Project 1$313,010
P41 · FY2024 · EB · contact PI
The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC$1,159,820
P41 · FY2023 · EB · contact PI
Biomimetic Matrix for Ex Vivo and In Vivo Activation of T Cells$479,444
R01 · FY2023 · EB
TR&D1: Engineering artificial Antigen Presenting Cells, aAPC, for Adoptive Immunotherapy$316,761
P41 · FY2023 · EB · contact PI
JH-TIE Admin Core$106,281
P41 · FY2023 · EB · contact PI
The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC$1,167,189
P41 · FY2022 · EB · contact PI
Biomimetic Matrix for Ex Vivo and In Vivo Activation of T Cells$479,444
R01 · FY2022 · EB
TR&D1: Engineering artificial Antigen Presenting Cells, aAPC, for Adoptive Immunotherapy$317,580
P41 · FY2022 · EB · contact PI
JH-TIE Admin Core$106,281
P41 · FY2022 · EB · contact PI
The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC$1,150,263
P41 · FY2021 · EB · contact PI
Biomimetic Matrix for Ex Vivo and In Vivo Activation of T Cells$469,854
R01 · FY2021 · EB
A high-throughput nanoparticle assay to characterize cancer neoepitope-specific T cells$400,511
R33 · FY2021 · CA · contact PI
TR&D1: Engineering artificial Antigen Presenting Cells, aAPC, for Adoptive Immunotherapy$311,229
P41 · FY2021 · EB · contact PI
JH-TIE Admin Core$105,760
P41 · FY2021 · EB · contact PI
The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC$1,173,739
P41 · FY2020 · EB · contact PI
Biomimetic Matrix for Ex Vivo and In Vivo Activation of T Cells$479,444
R01 · FY2020 · EB
A high-throughput nanoparticle assay to characterize cancer neoepitope-specific T cells$400,514
R33 · FY2020 · CA · contact PI
TR&D1: Engineering artificial Antigen Presenting Cells, aAPC, for Adoptive Immunotherapy$317,580
P41 · FY2020 · EB · contact PI
A high-throughput nanoparticle assay to characterize cancer neoepitope-specific T cells$163,750
R33 · FY2020 · CA · contact PI
JH-TIE Admin Core$107,918
P41 · FY2020 · EB · contact PI
The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC$1,707,351
P41 · FY2019 · EB · contact PI
JH-TIE Admin Core$613,693
P41 · FY2019 · EB · contact PI
A high-throughput nanoparticle assay to characterize cancer neoepitope-specific T cells$416,450
R33 · FY2019 · CA · contact PI
TR&D1: Engineering artificial Antigen Presenting Cells, aAPC, for Adoptive Immunotherapy$317,580
P41 · FY2019 · EB · contact PI
Immunoswitch: A novel nanoparticle-based approach to immunotherapy$245,625
R21 · FY2019 · EB · contact PI
Immunoswitch: A novel nanoparticle-based approach to immunotherapy$204,688
R21 · FY2018 · EB · contact PI
Antigen-specific T cell Redirectors, ATR, for immunotherapy$211,410
R21 · FY2016 · CA · contact PI
Use of aAPC for Melanoma Adoptive Immunotherapy$318,780
R01 · FY2015 · CA · contact PI
Antigen-specific T cell Redirectors, ATR, for immunotherapy$176,175
R21 · FY2015 · CA · contact PI
Use of aAPC for Melanoma Adoptive Immunotherapy$309,217
R01 · FY2014 · CA · contact PI
Use of aAPC for Melanoma Adoptive Immunotherapy$299,653
R01 · FY2013 · CA · contact PI
Artificial Immune Moduating (AIM??)Platform for the Treatment of Cancer$288,268
R43 · FY2013 · CA
Use of aAPC for Melanoma Adoptive Immunotherapy$57,204
R01 · FY2013 · CA · contact PI
Antigen receptor inputs: linking structural, molecular, and cellular responses$2,009,798
P01 · FY2012 · AI · contact PI
The influence of TCR spatial organization on the T cell responses$335,192
P01 · FY2012 · AI · contact PI
Use of aAPC for Melanoma Adoptive Immunotherapy$318,780
R01 · FY2012 · CA · contact PI
Administrative Core$123,184
P01 · FY2012 · AI · contact PI
Antigen receptor inputs: linking structural, molecular, and cellular responses$2,007,519
P01 · FY2011 · AI · contact PI
The influence of TCR spatial organization on the T cell responses$334,570
P01 · FY2011 · AI · contact PI
Use of aAPC for Melanoma Adoptive Immunotherapy$318,780
R01 · FY2011 · CA · contact PI
Administrative Core$125,294
P01 · FY2011 · AI · contact PI
Antigen receptor inputs: linking structural, molecular, and cellular responses$2,019,762
P01 · FY2010 · AI · contact PI
The influence of TCR spatial organization on the T cell responses$337,051
P01 · FY2010 · AI · contact PI
Administrative Core$126,949
P01 · FY2010 · AI · contact PI
Antigen receptor inputs: linking structural, molecular, and cellular responses$1,982,091
P01 · FY2009 · AI · contact PI
Antigen receptor inputs: linking structural, molecular, and cellular responses$355,465
P01 · FY2009 · AI · contact PI
The influence of TCR spatial organization on the T cell responses$332,165
P01 · FY2009 · AI · contact PI
Antigen Specific MOdulation of T Cell Responses$305,094
R01 · FY2009 · AI · contact PI
Administrative Core$123,990
P01 · FY2009 · AI · contact PI
Antigen receptor inputs: linking structural, molecular, and cellular responses$1,953,563
P01 · FY2008 · AI · contact PI
The influence of TCR spatial organization on the T cell responses$324,028
P01 · FY2008 · AI · contact PI
Use of aAPC for melanoma adoptive immunotherapy$317,808
R01 · FY2008 · CA · contact PI
Antigen Specific MOdulation of T Cell Responses$305,094
R01 · FY2008 · AI · contact PI
Profiling of influenza-specific immune responses in the elderly$184,534
R21 · FY2008 · AI · contact PI
Administrative Core$121,899
P01 · FY2008 · AI · contact PI
Use of aAPC for melanoma adoptive immunotherapy$317,808
R01 · FY2007 · CA · contact PI
Antigen Specific MOdulation of T Cell Responses$310,529
R01 · FY2007 · AI · contact PI
IMMUNOREGULATORY FUNCTIONS OF TCR AND MHC COMPLEXES$310,055
R01 · FY2007 · AI · contact PI
Profiling of influenza-specific immune responses in the elderly$245,758
R21 · FY2007 · AI · contact PI
Use of aAPC for melanoma adoptive immunotherapy$327,299
R01 · FY2006 · CA · contact PI
IMMUNOREGULATORY FUNCTIONS OF TCR AND MHC COMPLEXES$319,316
R01 · FY2006 · AI · contact PI
Antigen Specific MOdulation of T Cell Responses$318,828
R01 · FY2006 · AI · contact PI
Use of aAPC for melanoma adoptive immunotherapy$335,175
R01 · FY2005 · CA
IMMUNOREGULATORY FUNCTIONS OF TCR AND MHC COMPLEXES$327,000
R01 · FY2005 · AI
Antigen Specific Modulation of T Cell Responses$276,250
R01 · FY2005 · AI
Immune function in desensitized allograft recipients$245,250
R21 · FY2005 · AI
Use of aAPC for melanoma adoptive immunotherapy$335,175
R01 · FY2004 · CA
IMMUNOREGULATORY FUNCTIONS OF TCR AND MHC COMPLEXES$327,000
R01 · FY2004 · AI
Generation of Artificial Antigen Presenting Cells$245,250
R21 · FY2004 · HL
Immune function in desensitized allograft recipients$245,250
R21 · FY2004 · AI
ANTIGEN SPECIFIC MODULATION OF T CELL RESPONSES$402,255
R01 · FY2003 · AI
IMMUNOREGULATORY FUNCTIONS OF TCR AND MHC COMPLEXES$327,000
R01 · FY2003 · AI
Generation of Artificial Antigen Presenting Cells$245,250
R21 · FY2003 · HL
ANTIGEN SPECIFIC MODULATION OF T CELL RESPONSES$390,274
R01 · FY2002 · AI
Generation of Artificial Antigen Presenting Cells$245,250
R21 · FY2002 · HL
IMMUNOREGULATORY FUNCTIONS OF TCR AND MHC COMPLEXES$268,288
R01 · FY2001 · AI
ANTIGEN SPECIFIC MODULATION OF T CELL RESPONSES$251,446
R01 · FY2001 · AI
ANTIGEN SPECIFIC MODULATION OF T CELL RESPONSES$98,100
R01 · FY2001 · AI
ANTIGEN SPECIFIC MODULATION OF T CELL RESPONSES$318,803
R01 · FY2000 · AI
IMMUNOREGULATORY FUNCTIONS OF TCR AND MHC COMPLEXES$260,475
R01 · FY2000 · AI